Metabolism News and Research

Latest Metabolism News and Research

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center.

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010

Study explains link between morbid obesity and metabolic syndrome

Scientists have found that the fat cells and tissues of morbidly obese people and animals can reach a limit in their ability to store fat appropriately. Beyond this limit several biological processes conspire to prevent further expansion of fat tissue and in the process may trigger other health problems.

9 Nov 2010

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

Interleukin Genetics, Inc. today announced that on November 1, 2010 notification was received that it has been awarded two grants totaling $473,393 by the United States Government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the Company's genetic research projects related to obesity and osteoarthritis.

9 Nov 2010

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

bitop AG, a biotech company specializing in the development of Ectoin®-containing medical devices, announced the inclusion of the first patient into a clinical trial on the Ectoin inhalation solution in patients with inflammation and airway obstruction.

8 Nov 2010

MitoSciences awarded $244,000 grant under IRS Qualifying Therapeutic Discovery Project

MitoSciences Inc. today announces that it has been awarded a $244,000 grant under the IRS Qualifying Therapeutic Discovery Project. This award was made in support of MitoSciences' efforts to develop the world's most advanced set of assays for unlocking the role of metabolism in cancer and other critical diseases, and for helping researchers to design and monitor the most effective therapies for those conditions.

8 Nov 2010

People with SLE more likely to develop hematologic malignancies

People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Amgen wins Scrip Best New Drug award for Prolia

Amgen is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

8 Nov 2010

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.

7 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

Testosterone treatment for frailty in older men lacks long term benefits

The beneficial effects of six months of testosterone treatment on muscle mass, strength and quality of life in frail elderly men are not maintained at six months post-treatment, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

4 Nov 2010

Novel serum test may help diagnose early pregnancy location and outcome

Researchers may have identified a promising novel diagnostic biomarker for ectopic pregnancy, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). In the western world, deaths from ectopic pregnancy are not common but in the developing world one in ten women who are admitted with an ectopic pregnancy die.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

The Endocrine Society released a new clinical practice guideline for the nutritional and endocrine management of adults after bariatric surgery, including those with diabetes mellitus. The guideline features a series of evidence-based clinical recommendations developed by an expert task force. The guideline is published in the November 2010 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.

4 Nov 2010

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

4 Nov 2010

Regulus receives $488,989 grant under QTDP program

Regulus Therapeutics Inc. announced today that it has been awarded two grants totaling $488,989 under the Federal government's Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

Lifestyle changes and natural supplements can control blood sugar levels

The holiday season can make it challenging for people with diabetes to keep their blood sugar levels stable. Diabetes expert, Dr. Isaac Eliaz recommends prevention through a number of lifestyle changes and natural supplements.

3 Nov 2010

Study confirms human excrements contribute to water pollution

Every person emits the equivalent of approximately two tonnes of carbon dioxide a year from the time food is produced to when the human body excretes it, representing more than 20% of total yearly emissions. That is what a study by the Universidad de Almer-a says, confirming for the first time that human excrements contribute to water pollution, primarily with nitrogen and phosphorus.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

Metabolism News and Research

Latest Metabolism News and Research

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Study explains link between morbid obesity and metabolic syndrome

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

MitoSciences awarded $244,000 grant under IRS Qualifying Therapeutic Discovery Project

People with SLE more likely to develop hematologic malignancies

Amgen wins Scrip Best New Drug award for Prolia

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Testosterone treatment for frailty in older men lacks long term benefits

Novel serum test may help diagnose early pregnancy location and outcome

Phase III study suggests CYCLOSET tablets improve glycemic control

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Regulus receives $488,989 grant under QTDP program

Lifestyle changes and natural supplements can control blood sugar levels

Study confirms human excrements contribute to water pollution

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting